| CAS NO: | 64485-93-4 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 5g | 电议 |
| Cas No. | 64485-93-4 |
| 别名 | 头孢噻肟钠 ; Cefotaxim sodium; HR-756 sodium |
| 化学名 | (6R)-3-[(acetyloxy)methyl]-7R-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, monosodium salt |
| Canonical SMILES | [H][C@@]1([C@@H]2NC(/C(C3=CSC(N)=N3)=N\OC)=O)N(C(C([O-])=O)=C(COC(C)=O)CS1)C2=O.[Na+] |
| 分子式 | C16H16N5O7S2o Na |
| 分子量 | 477.5 |
| 溶解度 | ≥ 18.8mg/mL in DMSO |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | MIC:<0.1 μg/ml for S. pneumoniae Cefotaxime is a cephalosporin antibiotic. The cephalosporins, a class of β-lactam antibiotics originally derived from the fungus Acremonium, are indicated for the prophylaxis and treatment of infections caused by bacteria susceptible to this particular form of antibiotic. In vitro: Previous studies found that the in-vitro activity of cefotaxime against Staphylococcus au reus has ranged from 0.8 g to 8 μg/ml with 50% of isolates inhibited by 2 μg/ml and 90% by 4 μg/ml. Moreover, it was found that methicillin resistant S. aureus were resistant to cefotaxime with MIC values above 64 μg/ml. The cefotaxime MICs against S. pneumoniae were found to be below 0.1 μg/ml, with 90% inhibited by 0.04 μg/ml. Cefotaxime has also been shown to have excellent activity against Haemophilus injluenzae, such as β-lactamase-containing strains [1]. In vivo: An in-vivo study with the mouse model of Vibrio vulnificus infection was conducted to evaluate the efficacies of therapy with minocycline or cefotaxime alone and in combination. Results indicated that combination therapy with cefotaxime and minocycline was distinctly more advantageous than therapy with the single antibiotic regimen for the treatment of severe Vibrio vulnificus infections [2]. Clinical trial: A clinical trial was conducted to test the efficacy and safety of cefotaxime in the therapy of community-and hospital-acquired pneumonias. The results suggested that cefotaxime would be an affective and well-tolerated antimicrobial agent for the treatment of pneumonia becuause of susceptible organisms [3]. References: |
m.cnreagent.com